We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Renal Cell Carcinoma

Expert Opinion / Cases · July 28, 2015

Intolerance of mTOR Inhibitors

Written by
Andrew Fintel DO


Discuss This item Follow

No comments yet, be the first to start the discussion!

  • somarajan kunjuraman

    rrestart votrient

  • George Yaghmour

    Interesting case, I would consider re-challenge with mTOR with reduced dose. Other options Robert J. Motzer, M.D. el in NEJM Nivolumab has promising outcomes.

  • somarajan kunjuraman

    rechallenge with pazopenib

  • Oct 31, 2020

    Pending Moderator approval.

Further Reading